newsfilter
← Latest News
ACCESS Newswire·

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

  • Jaguar Health, Inc. announced voting results from its May 22, 2026 Annual Meeting which was adjourned until June 8, 2026.
  • Stockholders approved five proposals submitted at the Annual Meeting.
  • Details on the proposals are available in the company's Schedule 14A proxy statement filed with the SEC on April 30, 2026.
  • Lisa Conte, Jaguar's founder, president & CEO, will present virtually at the Emerging Growth Conference on Wednesday, June 10, 2026, from 12:35 to 1:05 PM Eastern.
  • Jaguar develops novel prescription drugs derived from plants for complicated gastrointestinal disease states.
  • Napo Pharmaceuticals, Inc. & Napo Therapeutics S.p.A. focus on crofelemer powder for oral solution to treat rare gastrointestinal disorders like microvillus inclusion disease & short bowel syndrome.
  • Magdalena Biosciences is a joint venture with Filament Health Corp. focused on plant-derived medicines for mental health indications.
  • An archived webcast of the presentation will be available on EmergingGrowth.com & the Emerging Growth YouTube Channel.
  • The press release includes forward-looking statements regarding future events that are subject to risks & uncertainties.